Cipla Ltd has announced an update regarding the recent inspection by the United States Food and Drug Administration (USFDA) at its manufacturing facility in Bommasandra, Bengaluru.

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to its earlier communication dated May 30, 2025, the company stated that the USFDA has concluded its inspection, conducted between May 26 and May 30, 2025.

As per an email received from the USFDA on August 4, 2025 (23:59 hrs IST), the inspection has been classified as "Voluntary Action Indicated" (VAI).